

This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 12-Feb-2024 **Revision Number** 1

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1. Product identifier

Product Code(s) DRE-C16581000

Product Name Pseudovardenafil

Form Not applicable

NOTE [8] - No registration number is given for this substance because it is under the threshold in REACH Article 6(1) and not subject to the registration requirements according to REACH Title II

EC No (EU Index No)

224788-34-5 CAS No.

Pure substance/mixture Substance

Formula C22H29N5O4S

Molecular weight 459.56

1.2. Relevant identified uses of the substance or mixture and uses advised against

Recommended use Laboratory use

Uses advised against No information available

1.3. Details of the supplier of the safety data sheet

Supplier

LGC Limited Queens Road **Teddington** Middlesex TW11 0LY UNITED KINGDOM :+44 (0) 20 8943 7000 Fax:+44(0)2089432767

eMail: gb@lgcstandards.com

Web: www.lgcstandards.com

For further information, please contact

E-mail address sds-request@lgcgroup.com

EGHS / EN Page 1 / 16



This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 12-Feb-2024 Revision Number 1

DRE-C16581000 - Pseudovardenafil

1.4. Emergency telephone number

Emergency Telephone For Hazardous Materials or Dangerous Goods Incident

Spill, Leak, Fire Exposure, or Accident

Call CHEMTREC:

USA & Canada 1-800-424-9300 Rest of the world +1 703-741-3877

Emergency Telephone - §45 - (EC)1272/2008		
Europe	112	
Austria	No information available	
Bulgaria		
Croatia		
Cyprus		
Czech Republic		
Denmark		
France		
Hungary		
Ireland		
Italy		
Lithuania		
Luxembourg		
Netherlands		
Norway		
Portugal		
Romania		
Slovakia		
Slovenia		
Spain		
Sweden		
Switzerland		

SECTION 2: Hazards identification

2.1. Classification of the substance or mixture

Classification according to

Regulation (EC) No. 1272/2008 [CLP]

Skin corrosion/irritation	Category 2 - (H315)
Serious eye damage/eye irritation	Category 2 - (H319)
Specific target organ toxicity — single exposure	Category 3 - (H335)
Category 3 Respiratory irritation	

EGHS / EN Page 2 / 16



This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 12-Feb-2024 Revision Number 1

DRE-C16581000 - Pseudovardenafil

Chronic aquatic toxicity Category 3 - (H412)

2.2. Label elements

Contains Pseudo Vardenafil



Signal word Warning

Hazard statements

H315 - Causes skin irritation

H319 - Causes serious eye irritation

H335 - May cause respiratory irritation

H412 - Harmful to aquatic life with long lasting effects

Precautionary Statements - EU (§28, 1272/2008)

P261 - Avoid breathing dust/fume/gas/mist/vapours/spray

P264 - Wash face, hands and any exposed skin thoroughly after handling

P280 - Wear protective gloves and eye/face protection

P312 - Call a POISON CENTER or doctor if you feel unwell

P403 + P233 - Store in a well-ventilated place. Keep container tightly closed

2.3. Other hazards

No information available.

This substance does not meet the PBT/vPvB criteria of REACH, annex XIII.

This product does not contain any known or suspected endocrine disruptors.

ine product document contains and the compa	2010 4 0114 0 01110 410 14 10 10 1	
Chemical name	EU - REACH (1907/2006) - Article 59(1)	EU - REACH (1907/2006) - Endocrine
	- Candidate List of Substances of Very	Disruptor Assessment List of
	High Concern (SVHC) for Authorisation	Substances
Pseudo Vardenafil	-	_

SECTION 3: Composition/information on ingredients

3.1 Substances

EGHS / EN Page 3 / 16



This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 12-Feb-2024 Revision Number 1

DRE-C16581000 - Pseudovardenafil

Chemical name	Weight-%	REACH registration number		Classification according to Regulation (EC) No.		M-Factor	M-Factor (long-term)
				1272/2008 [CLP]	limit (SCL)		
Pseudo Vardenafil	100	-	-	Skin Irrit. 2 (H315)			
224788-34-5				Eye Irrit. 2 (H319)			
				STOT SE 3 (H335)			
				Aquatic Chronic 3			
				(H412)			

Full text of H- and EUH-phrases: see section 16

Acute Toxicity Estimate
No information available

This product does not contain candidate substances of very high concern at a concentration >=0.1% (Regulation (EC) No. 1907/2006 (REACH), Article 59)

SECTION 4: First aid measures

4.1. Description of first aid measures

General advice Show this safety data sheet to the doctor in attendance.

Inhalation Remove to fresh air. IF exposed or concerned: Get medical advice/attention. Get medical

attention immediately if symptoms occur.

Eye contact Rinse immediately with plenty of water, also under the eyelids, for at least 15 minutes.

Remove contact lenses, if present and easy to do. Continue rinsing. Keep eye wide open while rinsing. Do not rub affected area. Get medical attention if irritation develops and

persists.

Skin contact Wash off immediately with soap and plenty of water for at least 15 minutes. Get medical

attention if irritation develops and persists.

Ingestion Do NOT induce vomiting. Rinse mouth. Never give anything by mouth to an unconscious

person. Call a doctor.

Self-protection of the first aider Avoid contact with skin, eyes or clothing. Wear personal protective clothing (see section 8).

4.2. Most important symptoms and effects, both acute and delayed

Symptoms May cause redness and tearing of the eyes. Burning sensation.

EGHS / EN Page 4 / 16



This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 12-Feb-2024 Revision Number 1

DRE-C16581000 - Pseudovardenafil

4.3. Indication of any immediate medical attention and special treatment needed

Note to doctorsTreat symptomatically.

SECTION 5: Firefighting measures

5.1. Extinguishing media

surrounding environment.

Large Fire CAUTION: Use of water spray when fighting fire may be inefficient.

Unsuitable extinguishing media Do not scatter spilled material with high pressure water streams.

5.2. Special hazards arising from the substance or mixture

Specific hazards arising from the

chemical

No information available.

5.3. Advice for firefighters

Special protective equipment and precautions for fire-fighters

Firefighters should wear self-contained breathing apparatus and full firefighting turnout gear.

Use personal protection equipment.

SECTION 6: Accidental release measures

6.1. Personal precautions, protective equipment and emergency procedures

Personal precautions Ensure adequate ventilation. Use personal protective equipment as required. Evacuate

personnel to safe areas. Avoid contact with skin, eyes or clothing.

Other information Refer to protective measures listed in Sections 7 and 8.

6.2. Environmental precautions

Environmental precautions Prevent further leakage or spillage if safe to do so.

6.3. Methods and material for containment and cleaning up

Methods for containment Prevent further leakage or spillage if safe to do so.

Methods for cleaning upTake up mechanically, placing in appropriate containers for disposal.

EGHS / EN Page 5 / 16



This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 12-Feb-2024 Revision Number 1

DRE-C16581000 - Pseudovardenafil

Prevention of secondary hazards Clean contaminated objects and areas thoroughly observing environmental regulations.

6.4. Reference to other sections

Reference to other sections See section 8 for more information. See section 13 for more information.

SECTION 7: Handling and storage

7.1. Precautions for safe handling

Advice on safe handling Handle in accordance with good industrial hygiene and safety practice. Avoid contact with

skin, eyes or clothing. Do not eat, drink or smoke when using this product. Take off contaminated clothing and wash it before reuse. Ensure adequate ventilation. Avoid breathing vapours or mists. In case of insufficient ventilation, wear suitable respiratory

equipment.

General hygiene considerations Avoid contact with skin, eyes or clothing. Do not eat, drink or smoke when using this

product. Wash hands before breaks and after work. Wear suitable gloves and eye/face

protection.

7.2. Conditions for safe storage, including any incompatibilities

Storage Conditions Please refer to the manufacturer's certificate for specific storage and transport temperature

conditions. Store only in the original receptacle unless other advice is given on the CoA.

Keep containers tightly closed in a dry, cool and well-ventilated place.

7.3. Specific end use(s)

Risk Management Methods (RMM) The information required is contained in this Safety Data Sheet.

SECTION 8: Exposure controls/personal protection

8.1. Control parameters

Exposure Limits This product, as supplied, does not contain any hazardous materials with occupational

exposure limits established by the region specific regulatory bodies.

Biological occupational exposure limits

This product, as supplied, does not contain any hazardous materials with biological limits established by the region specific regulatory bodies

EGHS / EN Page 6 / 16



This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 12-Feb-2024 Revision Number 1

DRE-C16581000 - Pseudovardenafil

Derived No Effect Level (DNEL)
Predicted No Effect Concentration

No information available. No information available.

(PNEC)

8.2. Exposure controls

Personal protective equipment

Eye/face protection Avoid contact with eyes. Wear safety glasses with side shields (or goggles). If splashes are

likely to occur, wear safety glasses with side-shields.

Hand protection The protective gloves to be used must comply with the specifications of EC Directive

89/686/EEC and the related standard EN374. Wear suitable gloves. Impervious gloves.

Gloves			
Duration of contact	PPE - Glove material	Glove thickness	Break through time
	Wear protective butyl		
	rubber gloves		

Skin and body protection Wear suitable protective clothing. Long sleeved clothing.

Respiratory protection No protective equipment is needed under normal use conditions. If exposure limits are

exceeded or irritation is experienced, ventilation and evacuation may be required.

General hygiene considerations Avoid contact with skin, eyes or clothing. Do not eat, drink or smoke when using this

product. Wash hands before breaks and after work. Wear suitable gloves and eye/face

protection.

Environmental exposure controls Do not allow into any sewer, on the ground or into any body of water.

SECTION 9: Physical and chemical properties

9.1. Information on basic physical and chemical properties

Physical state Solid Appearance Solid

Colourwhite to light yellowOdourNo information available.Odour thresholdNo information available

EGHS / EN Page 7/16



This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 12-Feb-2024 Revision Number 1

None known

DRE-C16581000 - Pseudovardenafil

PropertyValuesRemarks • MethodMelting point / freezing point180 - 182 °CNone knownInitial boiling point and boiling rangeNo data availableNone knownFlammabilityNo data availableNone known

Flammability Limit in Air

Upper flammability or explosive No data available

limits

Lower flammability or explosive No data available

limits

Flash pointNo data availableNone knownAutoignition temperatureNo data availableNone knownDecomposition temperatureNone known

pH No data available None known

pH (as aqueous solution) No data available No information available

Kinematic viscosityNo data availableNone knownDynamic viscosityNo data availableNone knownWater solubilityNo data availableNone known

Solubility(ies) Chloroform, Methanol, slightly soluble

Partition coefficientNo data availableNone knownVapour pressureNo data availableNone knownRelative densityNo data availableNone known

Bulk density
No data available

Relative vapour density

No data available

None known

Particle characteristics

Particle SizeNo information availableParticle Size DistributionNo information available

9.2. Other information

Molecular weight 459.56

Molecular formula C22H29N5O4S

9.2.1. Information with regards to physical hazard classes Not applicable

9.2.2. Other safety characteristics No information available

SECTION 10: Stability and reactivity

10.1. Reactivity

Reactivity No information available.

10.2. Chemical stability

EGHS / EN Page 8 / 16



This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 12-Feb-2024 Revision Number 1

DRE-C16581000 - Pseudovardenafil

Stability Stable under normal conditions.

Explosion data

Sensitivity to mechanical impact None. Sensitivity to static discharge None.

10.3. Possibility of hazardous reactions

Possibility of hazardous reactions
None under normal processing.

10.4. Conditions to avoid

Conditions to avoid None known based on information supplied.

10.5. Incompatible materials

Incompatible materials Strong acids. Strong bases. Strong oxidising agents.

Hazardous decomposition products None known based on information supplied.

SECTION 11: Toxicological information

11.1. Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure

Product Information

Inhalation Specific test data for the substance or mixture is not available. May cause irritation of

respiratory tract.

Eye contact Specific test data for the substance or mixture is not available. Causes serious eye irritation.

(based on components). May cause redness, itching, and pain.

Skin contact Specific test data for the substance or mixture is not available. Causes skin irritation. (based

on components).

Ingestion Specific test data for the substance or mixture is not available. Ingestion may cause

gastrointestinal irritation, nausea, vomiting and diarrhoea.

Symptoms related to the physical, chemical and toxicological characteristics

Symptoms Redness. May cause redness and tearing of the eyes.

Numerical measures of toxicity

EGHS / EN Page 9 / 16



This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 12-Feb-2024 Revision Number 1

DRE-C16581000 - Pseudovardenafil

No information available

Acute toxicity

Delayed and immediate effects as well as chronic effects from short and long-term exposure

Skin corrosion/irritation Classification based on data available for ingredients. Causes skin irritation. May cause skin

irritation.

Serious eye damage/eye irritation Classification based on data available for ingredients. Causes serious eye irritation.

Respiratory or skin sensitisation No information available.

Germ cell mutagenicity No information available.

Carcinogenicity No information available.

Reproductive toxicity No information available.

STOT - single exposure May cause respiratory irritation.

STOT - repeated exposureNo information available.

Aspiration hazard No information available.

11.2. Information on other hazards

11.2.1. Endocrine disrupting properties

Endocrine disrupting properties No information available.

EGHS / EN Page 10 / 16



This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 12-Feb-2024 Revision Number 1

DRE-C16581000 - Pseudovardenafil

11.2.2. Other information

Other adverse effects No information available.

SECTION 12: Ecological information

12.1. Toxicity

Ecotoxicity Harmful to aquatic life with long lasting effects.

12.2. Persistence and degradability

Persistence and degradability No information available.

12.3. Bioaccumulative potential

Bioaccumulation No information available.

12.4. Mobility in soil

Mobility in soil No information available.

12.5. Results of PBT and vPvB assessment

PBT and vPvB assessment No information available.

12.6. Endocrine disrupting properties

Endocrine disrupting properties No information available.

12.7. Other adverse effects

No information available.

SECTION 13: Disposal considerations

13.1. Waste treatment methods

Waste from residues/unused products

Dispose of in accordance with local regulations. Dispose of waste in accordance with environmental legislation.

EGHS / EN Page 11 / 16



This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 12-Feb-2024 Revision Number 1

DRE-C16581000 - Pseudovardenafil

Contaminated packaging Do not reuse empty containers.

SECTION 14: Transport information

IATA

14.1 UN number or ID number
 14.2 UN proper shipping name
 14.3 Transport hazard class(es)
 14.4 Packing group
 14.5 Environmental hazards
 Not regulated Not regulated Not applicable

14.6 Special precautions for user

Special Provisions None

IMDG

14.1UN number or ID numberNot regulated14.2UN proper shipping nameNot regulated14.3Transport hazard class(es)Not regulated14.4Packing groupNot regulated14.5Marine pollutantNot applicable

14.6 Special precautions for user

Special Provisions
None No information available
No information available

according to IMO instruments

RID

14.1 UN number or ID number
 14.2 UN proper shipping name
 14.3 Transport hazard class(es)
 14.4 Packing group
 14.5 Environmental hazards
 Not regulated Not regulated Not applicable

14.6 Special precautions for user

Special Provisions None

<u>ADR</u>

14.1 UN number or ID number
 14.2 UN proper shipping name
 14.3 Transport hazard class(es)
 14.4 Packing group
 14.5 Environmental hazards
 Not regulated
 Not regulated
 Not regulated
 Not regulated
 Not applicable

14.6 Special precautions for user

Special Provisions None

SECTION 15: Regulatory information

EGHS / EN Page 12 / 16



This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 12-Feb-2024 Revision Number 1

DRE-C16581000 - Pseudovardenafil

15.1. Safety, health and environmental regulations/legislation specific for the substance or mixture

National regulations

Germany

Water hazard class (WGK)

slightly hazardous to water (WGK 1)

Poland

SDS created according to the following Polish regulation: Act of February 25, 2011 on chemical substances and their mixtures (Journal of Laws of 2018, item 143, as amended). Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, Evaluation, Authorization and Restriction of Chemicals (REACH), establishing the European Chemicals Agency (EC) as amended. Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labeling and packaging of substances and mixtures, as amended. Regulation of the Minister of Health of 10 August 2012 on the criteria and method of classifying chemical substances and their mixtures (Journal of Laws of 2012, item 1018). Regulation of the Minister of Health of 20 April 2012 on labeling packaging of hazardous substances and mixtures and some mixtures (Journal of Laws of 2012, item 445). Regulation of the Minister of Family, Labor and Social Policy of 12 June 2018 on the maximum allowable concentrations and intensities of factors harmful to health in the work environment (Journal of Laws of 2018, item 1286). Announcement of the Minister of Economy, Labor and Social Policy of August 28, 2003 on the publication of the unified text of the Ordinance of the Minister of Labor and Social Policy on general health and safety at work regulations (Journal of Laws of 2003, No. 169, item 1650). Regulation of the Minister of Health of 30 December 2004 on occupational safety and health related to the presence of chemical agents in the workplace (Journal of Laws of 2005, No. 11, item 86). Act of December 14, 2012 on waste (Journal of Laws of 2013, item 21) Regulation of the Minister of Health of December 30, 2004 on occupational health and safety related to the presence of chemical agents in the workplace (Journal U. of 2005, No. 11, item 86). Waste Act of December 14, 2012 (Journal of Laws of 2013, item 21). Act of 13 June 2013 on the management of packaging and packaging waste, Journal of Laws 2013, item 888). Government statement of September 24, 2002 - European Agreement on the International Carriage of Dangerous Goods by Road (ADR) (Journal of Laws No. 194, item 1629 and Journal of Laws of 2003, No. 207, item 2013 and 2014).

European Union

Take note of Directive 98/24/EC on the protection of the health and safety of workers from the risks related to chemical agents at work.

Authorisations and/or restrictions on use:

This product does not contain substances subject to authorisation (Regulation (EC) No. 1907/2006 (REACH), Annex XIV) This product does not contain substances subject to restriction (Regulation (EC) No. 1907/2006 (REACH), Annex XVII)

EGHS / EN Page 13 / 16



This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 12-Feb-2024 Revision Number 1

DRE-C16581000 - Pseudovardenafil

DIRECTIVE (EU) 2021/1187 on the marketing and use of explosives precursors

Not applicable

Persistent Organic Pollutants

Not applicable

Ozone-depleting substances (ODS) regulation (EC) 1005/2009

Not applicable

International Inventories

TSCA LGC has not confirmed that the chemical substances in this product are on the TSCA

Inventory, and LGC is distributing this product solely for use either in applications statutorily exempt from TSCA and regulated under other laws (e.g., FFDCA, FIFRA) or in research and development activities in accordance with the TSCA Inventory R&D exemption provided

at 40 CFR 720.36. It is the end-user's responsibility to understand and follow the

requirements that apply to its use of this product.

DSL/NDSL
Contact supplier for inventory compliance status

Legend:

TSCA - United States Toxic Substances Control Act Section 8(b) Inventory

DSL/NDSL - Canadian Domestic Substances List/Non-Domestic Substances List

EINECS/ELINCS - European Inventory of Existing Chemical Substances/European List of Notified Chemical Substances

ENCS - Japan Existing and New Chemical Substances

IECSC - China Inventory of Existing Chemical Substances

KECL - Korean Existing and Evaluated Chemical Substances

PICCS - Philippines Inventory of Chemicals and Chemical Substances

AICS - Australian Inventory of Chemical Substances

15.2. Chemical safety assessment

Chemical Safety Report A Chemical Safety Assessment is not required for this substance

EGHS / EN Page 14 / 16



This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 12-Feb-2024 Revision Number 1

DRE-C16581000 - Pseudovardenafil

SECTION 16: Other information

Key or legend to abbreviations and acronyms used in the safety data sheet

Full text of H-Statements referred to under section 3

H315 - Causes skin irritation

H319 - Causes serious eye irritation

H335 - May cause respiratory irritation

H412 - Harmful to aquatic life with long lasting effects

Legend

SVHC: Substances of Very High Concern for Authorisation:

Legend Section 8: Exposure controls/personal protection

TWA TWA (time-weighted average) STEL STEL (Short Term Exposure Limit)

Ceiling Maximum limit value Sk* Skin designation

Classification procedure	
Classification according to Regulation (EC) No. 1272/2008 [CLP]	Method Used
Acute oral toxicity	Calculation method
Acute dermal toxicity	Calculation method
Acute inhalation toxicity - gas	Calculation method
Acute inhalation toxicity - Vapour	Calculation method
Acute inhalation toxicity - dust/mist	Calculation method
Skin corrosion/irritation	Calculation method
Serious eye damage/eye irritation	Calculation method
Respiratory sensitisation	Calculation method
Skin sensitisation	Calculation method
Mutagenicity	Calculation method
Carcinogenicity	Calculation method
Reproductive toxicity	Calculation method
STOT - single exposure	Calculation method
STOT - repeated exposure	Calculation method
Acute aquatic toxicity	Calculation method
Chronic aquatic toxicity	Calculation method
Aspiration hazard	Calculation method
Ozone	Calculation method

Key literature references and sources for data used to compile the SDS

Agency for Toxic Substances and Disease Registry (ATSDR) U.S. Environmental Protection Agency ChemView Database

EGHS / EN Page 15 / 16



This safety data sheet was created pursuant to the requirements of: Regulation (EC) No. 1907/2006 and Regulation (EC) No. 1272/2008

Revision date 12-Feb-2024 Revision Number 1

DRE-C16581000 - Pseudovardenafil

European Food Safety Authority (EFSA)

EPA (Environmental Protection Agency)

Acute Exposure Guideline Level(s) (AEGL(s))

U.S. Environmental Protection Agency Federal Insecticide, Fungicide, and Rodenticide Act

U.S. Environmental Protection Agency High Production Volume Chemicals

Food Research Journal

Hazardous Substance Database

International Uniform Chemical Information Database (IUCLID)

Japan GHS Classification

. Australian National Industrial Chemicals Notification and Assessment Scheme (NICNAS)

NIOSH (National Institute for Occupational Safety and Health)

National Library of Medicine's ChemID Plus (NLM CIP)

National Library of Medicine's PubMed database (NLM PUBMED)

National Toxicology Program (NTP)

New Zealand's Chemical Classification and Information Database (CCID)

Organisation for Economic Co-operation and Development Environment, Health, and Safety Publications

Organisation for Economic Co-operation and Development High Production Volume Chemicals Programme

Organisation for Economic Co-operation and Development Screening Information Data Set

World Health Organization

Revision date 12-Feb-2024

This material safety data sheet complies with the requirements of Regulation (EC) No. 1907/2006 Disclaimer

The information in this safety data sheet (SDS) has been prepared with due care and is true and accurate to the best of our knowledge. The user must determine the suitability of the information for its particular purpose, ensure compliance with existing laws and regulations, and be aware that other or additional safety or performance considerations may arise when using, handling and/ or storing the material. The information in this SDS does not purport to be all inclusive or a guarantee as to the properties of the material supplied, and should be used only as a guide. LGC makes no warranties or representations as to the accuracy and completeness of the information contained herein, shall not be held responsible for the suitability of this information for the user's intended purposes or the consequences of such use, and shall not be liable for any damage or loss, howsoever arising, direct or otherwise.

End of Safety Data Sheet

EGHS / EN Page 16 / 16